Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: June 2017

Rutgers-New Brunswick Rated One of Top 100 Research Universities in the World; Ranked No. 31 in U.S.

New Brunswick, NJ, June 26, 2017 — NJBIZ reported that Rutgers-New Brunswick was one of 37 universities in the United States to be ranked among the Top 100 research-intensive universities in the world, according to the prestigious CWTS Leiden Rankings.

Rutgers ranked No. 77 in the world, but No. 31 among schools based in the United States.

Rutgers was behind Cornell (No. 26), Washington University in St. Louis (27) and New York University (29). Continue reading

Monmouth University Interim President Grey Dimenna to Stay Until June 2019

Grey Dimenna

West Long Branch, NJ, June 26, 2017 — Grey Dimenna, plucked out of retirement to fill in as president of Monmouth University, has extended his contract and will serve until June 2019, the school said.

Dimenna said the temporary appointment won’t prevent the West Long Branch university from taking steps to tackle pressing issues facing higher education, including its cost.

“Although I’m only going to be president a couple years, there’s a lot of important things to do,” Dimenna, 63, said. “There’s a lot of momentum we need to keep going.” Continue reading

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

New Jersey Innovation Institute Introduces Two Groundbreaking Biopharmaceutical Centers

Newark, NJ, June 24, 2017 — Companies in every sector are realizing that manufacturing matters.  For the biopharmaceutical industry, innovation is not about reducing unit part costs; instead, process technology is a strategic tool to reduce time to market, ensure consistent product quality and streamline regulatory approval.

As rapidly as science is advancing drug discovery, so too, must production technology keep pace.  But where will such innovation happen?

The New Jersey Innovation Institute (NJII) is answering this question. Continue reading

Ex-Roche Campus Reinvented as ‘On3’ Science Center; Developer Seeks to Create Mini-Metropolis in the Suburbs’ for Life Sciences

Nutley, NJ, June 23, 2017 — Owen Proctor reports in The Record/NorthJersey.com that the former Hoffmann-La Roche campus that borders Clifton and Nutley has a new name.

“On3” seeks to incorporate living, working and playing in the Route 3 site, according to Prism Capital Partners’ principal Eugene Diaz. He described the redevelopment as “a mini-metropolis in the suburbs.”

The firm wants to reinvent the 116-acre campus that the pharmaceutical giant began vacating in 2012, creating a synergy among like-minded businesses geared toward life sciences. Continue reading

National Institute on Aging Report: Promising But Inconclusive Evidence on Interventions to Prevent Cognitive Decline, Dementia

Bethesda, MD, June 23, 2017 — The public is enormously concerned about dementia and cognitive impairment, and a wide range of programs and products, such as diets, exercise regimens, games, and supplements, purport to keep these conditions at bay.

It is difficult for individuals, health care providers and policy makers to ascertain what has been demonstrated to prevent or reduce risk.

To help sort through the data and to understand the quality and weight of current evidence for possible interventions, the National Institute on Aging (NIA) at the National Institutes of Health (NIH), commissioned experts for an extensive scientific review and to provide recommendations for public health messaging and future research priorities. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

NIH Abandons Plans to Limit Individual Research Funding, Creates Special Fund

Washington, DC, June 23, 2017 — After much criticism, the National Institutes of Health (NIH) announced that it will abandon the Grant Support Index (GSI) plan – a strategy to bolster NIH funding support for the next generation of researchers by placing limits on individual research funding which SSTI previously covered.

Instead, NIH will launch the Next Generation Researchers Initiative (NGRI) that will allocate $1.1 billion over the next five years to support nearly 2,400 new grants for early and mid-career researchers whose grant proposals receive high scores, but fall short of receiving funds. Continue reading

Opinion: Allergan Chief Brent Saunders on Helping Our Daughters Stick with STEM (Science, Technology, Engineering & Math)’

Brent L. Saunders

Parsippany, NJ, June 22, 2017Brent L. Saunders, Chairman, President and Chief Executive Officer at Allergan plc, yesterday wrote the following opinion piece on his CEO blog:

As the CEO of a biopharma company that is focused on innovation for patients, I was struck recently by the scientific thinking and discovery happening at an event that might surprise you: my daughter’s high school science fair.

The projects tackled scientific mysteries such as why different shades of color trigger a neurological response including mood, how mathematical statistics explain the so-called “Birthday Paradox” and more. Continue reading

GEN Publishes 2017 Top 10 U.S. Biopharma Clusters List; New Jersey/New York Again Ranked No. 3

New Rochelle, NY, June 22, 2017 — Genetic Engineering & Biotechnology News (GEN) on June 5 published its 2017 Top 10 US Biopharma Clusters list.  New Jersey/New York is number three on the list, the same position it was on GEN’s 2016 Top 10 list.

Greater Philadelphia ranks at number seven.

GEN’s Top 10 U.S. Biopharma Clusters are:

  1. Boston-Cambridge
  2. San Francisco Bay Area
  3. New Jersey/New York
  4. San Diego
  5. Maryland, Virginia and DC Metro
  6. San Diego
  7. Greater Philadelphia
  8. Seattle
  9. Raleigh/Durham (includes Research Triangle Park)
  10. Los Angeles/Orange County
  11. Chicagoland

Continue reading